Partial
Needs Review
Patient Risk:
Moderate
Summary
Several dosing-pattern statements align with the provided label sections, but multiple pediatric weight-based dosing claims are contradicted or insufficiently qualified, and the audit content provided does not address other label elements (e.g., contraindications/boxed warnings), limiting full prescribing-information alignment verification.
Category Scores
Accurate Statements
Cosentyx regimens typically include an initial higher-frequency loading period followed by a less frequent maintenance schedule.
2.3 (Adults with PsO); 2.4 (Adults with PsA with loading); 2.6 (Adults with AS with loading): Weeks 0,1,2,3,4 then every 4 weeks thereafter.
The duration of the Cosentyx loading period and the maintenance frequency depend on the specific condition.
Partially supported/unclear from provided label excerpts; several indications show the same SC loading at Weeks 0–4 and maintenance q4w, while adult PsA/AS IV regimens are mg/kg-based and differ from SC.
The specific Cosentyx adult dosing amount and frequency depend on the condition being treated.
2.3 (Adults with PsO: 300 mg q4w after Weeks 0–4; 150 mg may be acceptable for some); 2.4 (Adults with PsA: with/without loading; possible increase to 300 mg q4w); 2.6 (Adults with AS: with/without loading; possible increase to 300 mg q4w).
The exact Cosentyx dosing regimen can differ between indications such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.
2.3 vs 2.4 vs 2.6 provide different SC and IV regimens and with/without loading options.
Unsupported Statements
Cosentyx regimens typically include an initial higher-frequency loading period followed by a less frequent maintenance schedule.
Supported for adult SC regimens where loading is used, but not universally true because adult PsA and AS regimens also include options without a loading dosage.
The duration of the Cosentyx loading period and the maintenance frequency depend on the specific condition.
The provided excerpts show the SC loading interval (Weeks 0–4) and SC maintenance interval (every 4 weeks thereafter) appearing consistent across several conditions; variability is more clearly reflected by indication and whether loading is used, and by SC vs IV regimen differences.
Contradictions
High
AI Statement
Cosentyx (secukinumab) dosing is not based on patient weight.
Label Reference
2.3 pediatric plaque psoriasis (6 years+): explicitly states recommended weight-based dosage with <50 kg vs ≥50 kg; 2.5 pediatric PsA: weight-based with ≥15 kg/<50 kg vs ≥50 kg; 2.7 pediatric AS (12+): weight-based with <50 kg vs ≥50 kg.
High
AI Statement
Cosentyx dosing for pediatric patients is not weight-based.
Label Reference
2.3, 2.5, 2.7: each describes pediatric dosing as weight-based with specified weight cutoffs.
Important Omissions
The claims do not address that pediatric dosing in the provided label sections is weight-based (with specific weight cutoffs) even though multiple pediatric dose statements were made. This omission is material given the explicit contradiction.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
Contradicted statements about whether pediatric dosing is weight-based could lead to incorrect dosing interpretation for pediatric patients if used as guidance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Needs Review
Primary Issue
Two pediatric weight-based dosing claims are directly contradicted by the provided label excerpts (2.3, 2.5, 2.7). Several 'typically/depends on condition' generalizations are only partially supported.
Suggested Improvement
Revise statements to reflect that pediatric dosing is weight-based with specified cutoffs and that adult loading is option-dependent (there are adult regimens with and without loading) and that SC interval appears consistent in provided excerpts while differences may relate to indication, loading option, and SC vs IV regimen.